Pharmacological treatment of idiopathic pulmonary fibrosis: current approaches, unsolved issues, and future perspectives

Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a 5-year survival of approximately 20%. The disease primarily occurs in elderly patients. IPF is a highly heterogeneous disorder with a clinical course that varies from prolonged periods of stability to episodes of rapid deteriorati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kreuter, Michael (VerfasserIn) , Bonella, Francesco (VerfasserIn) , Wijsenbeek, Marlies (VerfasserIn) , Maher, Toby M. (VerfasserIn) , Spagnolo, Paolo (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 08 Dec 2015
In: BioMed research international
Year: 2015, Jahrgang: 2015
ISSN:2314-6141
DOI:10.1155/2015/329481
Online-Zugang:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1155/2015/329481
Verlag, lizenzpflichtig, Volltext: https://www.hindawi.com/journals/bmri/2015/329481/
Volltext
Verfasserangaben:Michael Kreuter, Francesco Bonella, Marlies Wijsenbeek, Toby M. Maher, and Paolo Spagnolo

MARC

LEADER 00000caa a2200000 c 4500
001 1725827883
003 DE-627
005 20230428072924.0
007 cr uuu---uuuuu
008 200729s2015 xx |||||o 00| ||eng c
024 7 |a 10.1155/2015/329481  |2 doi 
035 |a (DE-627)1725827883 
035 |a (DE-599)KXP1725827883 
035 |a (OCoLC)1341348741 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Kreuter, Michael  |d 1972-  |e VerfasserIn  |0 (DE-588)122645995  |0 (DE-627)082066795  |0 (DE-576)293362742  |4 aut 
245 1 0 |a Pharmacological treatment of idiopathic pulmonary fibrosis  |b current approaches, unsolved issues, and future perspectives  |c Michael Kreuter, Francesco Bonella, Marlies Wijsenbeek, Toby M. Maher, and Paolo Spagnolo 
264 1 |c 08 Dec 2015 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 29.07.2020 
520 |a Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a 5-year survival of approximately 20%. The disease primarily occurs in elderly patients. IPF is a highly heterogeneous disorder with a clinical course that varies from prolonged periods of stability to episodes of rapid deterioration. In the last decade, improved understanding of disease mechanisms along with a more precise disease definition has allowed the design and completion of a number of high-quality clinical trials. Yet, until recently, IPF was essentially an untreatable disease. Finally, pirfenidone and nintedanib, two compounds with antifibrotic properties, have consistently proven effective in reducing functional decline and disease progression in IPF. This is a major breakthrough for patients and physicians alike, but there is still a long way to go. In fact, neither pirfenidone nor nintedanib is a cure for IPF, and most patients continue to progress despite treatment. As such, comprehensive care of patients with IPF, including management of comorbidities/complications and physical debility and timely referral for palliative care or, in a small number of highly selected patients, lung transplantation, remains essential. Several agents with high potential are currently being tested and many more are ready to be evaluated in clinical trials. 
700 1 |a Bonella, Francesco  |e VerfasserIn  |4 aut 
700 1 |a Wijsenbeek, Marlies  |e VerfasserIn  |4 aut 
700 1 |a Maher, Toby M.  |e VerfasserIn  |4 aut 
700 1 |a Spagnolo, Paolo  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t BioMed research international  |d [Hoboken, NJ] : Wiley, 2013  |g (2015) Artikel-Nummer 329481, 10 Seiten  |h Online-Ressource  |w (DE-627)734738145  |w (DE-600)2698540-8  |w (DE-576)377910473  |x 2314-6141  |7 nnas  |a Pharmacological treatment of idiopathic pulmonary fibrosis current approaches, unsolved issues, and future perspectives 
773 1 8 |g volume:2015  |g year:2015  |g extent:10  |a Pharmacological treatment of idiopathic pulmonary fibrosis current approaches, unsolved issues, and future perspectives 
856 4 0 |u https://doi.org/10.1155/2015/329481  |x Resolving-System  |x Verlag  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.hindawi.com/journals/bmri/2015/329481/  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200729 
993 |a Article 
994 |a 2015 
998 |g 122645995  |a Kreuter, Michael  |m 122645995:Kreuter, Michael  |d 910000  |d 950000  |d 950900  |d 50000  |e 910000PK122645995  |e 950000PK122645995  |e 950900PK122645995  |e 50000PK122645995  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN1725827883  |e 3731887290 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"subtitle":"current approaches, unsolved issues, and future perspectives","title":"Pharmacological treatment of idiopathic pulmonary fibrosis","title_sort":"Pharmacological treatment of idiopathic pulmonary fibrosis"}],"relHost":[{"title":[{"title":"BioMed research international","title_sort":"BioMed research international"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"Wiley ; Hindawi","dateIssuedDisp":"2024-","dateIssuedKey":"2024","publisherPlace":"[Hoboken, NJ] ; New York [u.a.]"}],"disp":"Pharmacological treatment of idiopathic pulmonary fibrosis current approaches, unsolved issues, and future perspectivesBioMed research international","language":["eng"],"recId":"734738145","part":{"volume":"2015","text":"(2015) Artikel-Nummer 329481, 10 Seiten","extent":"10","year":"2015"},"note":["Gesehen am 13.01.25"],"pubHistory":["2013 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"doi":["10.1155/2738"],"issn":["2314-6141"],"zdb":["2698540-8"],"eki":["734738145"]}}],"id":{"doi":["10.1155/2015/329481"],"eki":["1725827883"]},"name":{"displayForm":["Michael Kreuter, Francesco Bonella, Marlies Wijsenbeek, Toby M. Maher, and Paolo Spagnolo"]},"physDesc":[{"extent":"10 S."}],"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"08 Dec 2015"}],"language":["eng"],"person":[{"family":"Kreuter","role":"aut","roleDisplay":"VerfasserIn","given":"Michael","display":"Kreuter, Michael"},{"family":"Bonella","roleDisplay":"VerfasserIn","role":"aut","given":"Francesco","display":"Bonella, Francesco"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Marlies","display":"Wijsenbeek, Marlies","family":"Wijsenbeek"},{"family":"Maher","given":"Toby M.","roleDisplay":"VerfasserIn","role":"aut","display":"Maher, Toby M."},{"given":"Paolo","role":"aut","roleDisplay":"VerfasserIn","display":"Spagnolo, Paolo","family":"Spagnolo"}],"recId":"1725827883","note":["Gesehen am 29.07.2020"],"type":{"media":"Online-Ressource","bibl":"article-journal"}} 
SRT |a KREUTERMICPHARMACOLO0820